Illumina, Inc. (NASDAQ:ILMN) Stock Holdings Cut by Baillie Gifford & Co.

Baillie Gifford & Co. reduced its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 35.4% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 3,622,813 shares of the life sciences company’s stock after selling 1,982,362 shares during the quarter. Baillie Gifford & Co. owned about 2.27% of Illumina worth $472,451,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in Illumina by 0.4% during the 1st quarter. Vanguard Group Inc. now owns 18,245,041 shares of the life sciences company’s stock valued at $2,505,409,000 after purchasing an additional 66,528 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Illumina by 7.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 3,039,538 shares of the life sciences company’s stock valued at $317,267,000 after purchasing an additional 204,043 shares in the last quarter. Capital World Investors boosted its stake in Illumina by 41.1% during the 1st quarter. Capital World Investors now owns 2,753,504 shares of the life sciences company’s stock valued at $378,111,000 after purchasing an additional 801,814 shares in the last quarter. Primecap Management Co. CA boosted its stake in Illumina by 462.5% during the 2nd quarter. Primecap Management Co. CA now owns 2,428,760 shares of the life sciences company’s stock valued at $253,514,000 after purchasing an additional 1,997,010 shares in the last quarter. Finally, GUARDCAP ASSET MANAGEMENT Ltd boosted its stake in Illumina by 1.1% during the 1st quarter. GUARDCAP ASSET MANAGEMENT Ltd now owns 2,068,869 shares of the life sciences company’s stock valued at $284,097,000 after purchasing an additional 22,067 shares in the last quarter. 89.42% of the stock is owned by institutional investors.

Illumina Price Performance

Shares of NASDAQ:ILMN opened at $151.50 on Tuesday. Illumina, Inc. has a fifty-two week low of $92.26 and a fifty-two week high of $156.66. The business has a 50-day moving average of $138.50 and a two-hundred day moving average of $123.77. The stock has a market capitalization of $24.03 billion, a P/E ratio of -15.21 and a beta of 1.13. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 0.86.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.26. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The business had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.08 billion. During the same quarter in the previous year, the firm earned $0.33 EPS. The firm’s revenue was down 3.5% compared to the same quarter last year. On average, equities research analysts predict that Illumina, Inc. will post 4.11 EPS for the current fiscal year.

Analyst Ratings Changes

ILMN has been the subject of a number of research reports. Canaccord Genuity Group increased their price target on Illumina from $130.00 to $145.00 and gave the company a “hold” rating in a research note on Tuesday, November 5th. HSBC upgraded Illumina from a “hold” rating to a “buy” rating and set a $180.00 target price on the stock in a report on Thursday, October 17th. TD Cowen lifted their target price on Illumina from $166.00 to $177.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. Piper Sandler decreased their target price on Illumina from $195.00 to $185.00 and set an “overweight” rating on the stock in a report on Monday. Finally, Robert W. Baird lifted their price target on Illumina from $124.00 to $139.00 and gave the company a “neutral” rating in a report on Wednesday, November 6th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, fourteen have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Illumina has an average rating of “Moderate Buy” and an average target price of $163.71.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.